Navigation Links
Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
Date:1/10/2012

RANCHO CORDOVA, Calif., Jan. 10, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store human cell concentrates, said today it has entered into a five year collaboration with Arthrex, Inc., under which Arthrex will market ThermoGenesis' Res-Q® 60 (Res-Q) System technology for use in the preparation of autologous Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC).

Based in Naples, Florida, Arthrex is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. The company has developed more than 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures used worldwide.

The Res-Q technology is a point-of-care platform designed for the preparation of cell concentrates. In June, 2011, the Company received FDA clearance of its 510(k) submission for use of Res-Q technology for the safe and rapid preparation of autologous PRP from a small sample of blood. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.

About Arthrex

Arthrex, headquartered in Naples, FL, is a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons. More than 5,000 products for arthroscopic and minimally invasive orthopaedic surgical procedures have been developed by Arthrex and are currently marketed worldwide. For more information, visit www.arthrex.com.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

 


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces Webcast of Presentation at OneMedForum Conference
2. ThermoGenesis Corp. to Announce First Quarter Fiscal 2012 Results on November 10, 2011
3. ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent
4. ThermoGenesis Presentation at Rodman & Renshaw Conference
5. ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao
6. ThermoGenesis Announces Webcast of Presentation at OnemedForum Conference
7. ThermoGenesis Reports Third Quarter Fiscal 2011 Results; Major Progress Achieved in China & India
8. ThermoGenesis Corp. to Announce Third Quarter Fiscal 2011 Results On May 5, 2011
9. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
10. Major China Regenerative Medicine Company Adopts ThermoGenesis Cord Blood Stem Cell Processing And Storage Technologies
11. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... International plc (NASDAQ: ENDP ) today announced ... network, the Company will be ceasing operations and closing ... Alabama . The closure of the facilities is ... 18 months. The Huntsville location ... and these restructuring actions are intended to better match ...
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., the ... testing, strengthening and rehabilitation equipment, today announced the national ... MedX is considered the gold standard for the treatment ... specialized medical strengthening equipment. ... with the physician or practice who prescribe the MedX ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... “Nana Nana Boo Boo”: ... of being kind to others. “Nana Nana Boo Boo” is the creation of published ... , Published by Christian Faith Publishing, Michael Rush’s new book presents the importance ...
(Date:7/24/2017)... ... July 24, 2017 , ... “Journey to the Light: The Quest for Happiness ... young woman’s path to finding herself. “Journey to the Light: The Quest for ... Grayson, an experienced writer of newsletters, manuals, and articles, who has recently decided to ...
(Date:7/23/2017)... ... July 24, 2017 , ... Three experts will be ... 59th Annual Meeting & Exhibition, to be held in Denver, CO on July ... and journalists can visit the AAPM Facebook page to watch three speakers present ...
(Date:7/23/2017)... ... July 23, 2017 , ... A 20-year-long study ... Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports growing ... disease offers very few benefits. , In the cases involved with this study, ...
(Date:7/23/2017)... ... July 23, 2017 , ... Better education to coaches and ... their work today at the American Orthopaedic Society for Sports Medicine’ ... one to prospectively document the association between sports specialization and lower extremity injuries ...
Breaking Medicine News(10 mins):